Evidence map›Paper›PMID 39044428›Full record

ArticleHGG advances2024

Discovery of new myositis genetic associations through leveraging other immune-mediated diseases.

Guillermo Reales, Christopher I Amos, Olivier Benveniste, Hector Chinoy, Jan De Bleecker, Boel De Paepe, Andrea Doria, Peter K Gregersen, Janine A Lamb, Vidya Limaye and 16 more

Abstract read
In one paragraph

Article in HGG advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Guillermo RealesCambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), University of Cambridge, Cambridge, UK; Department of Medicine, University of Cambridge, Cambridge, UK. Electronic address: grealesm@gmail.com.
Christopher I AmosDepartment of Medicine, Baylor College of Medicine, Houston, TX, USA.
Olivier BenvenisteDepartment of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière Hospital, Paris, France.
Hector ChinoyDepartment of Rheumatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, UK; Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
Jan De BleeckerDepartment of Neurology, Ghent University, Ghent, Belgium; Neuromuscular Reference Center, Ghent University Hospital, Ghent, Belgium.
Boel De PaepeDepartment of Neurology, Ghent University, Ghent, Belgium; Neuromuscular Reference Center, Ghent University Hospital, Ghent, Belgium.
Andrea DoriaRheumatology Unit, Department of Medicine, University of Padova, Padova, Italy.
Peter K GregersenThe Robert S. Boas Center for Genomics and Human Genetics, The Feinstein Institute, Manhasset, NY, USA.
Janine A LambEpidemiology and Public Health Group, Division of Population Health, Health Services Research & Primary Care, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Vidya LimayeRheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia; Discipline of Medicine, Adelaide University, Adelaide, South Australia, Australia.
Ingrid E LundbergDivision of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Pedro M MachadoDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology. London, UK; Centre for Rheumatology, UCL Division of Medicine, University College London, London, UK.
Britta MaurerDepartment of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Frederick W MillerEnvironmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, USA.
Øyvind MolbergDepartment of Rheumatology, Oslo University Hospital, Oslo, Norway.
Lauren M PachmanChildren's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Leonid PadyukovDivision of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Timothy R RadstakeDepartment of Rheumatology and Clinical Immunology, University Medical Center, Utrecht, the Netherlands.
Ann M ReedDepartment of Pediatrics, Duke University, Durham, NC, USA.
Lisa G RiderEnvironmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, USA.
Simon RothwellCentre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Albert Selva-O'CallaghanInternal Medicine Department, Vall d'Hebron General Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain.
Jiri VencovskýInstitute of Rheumatology and Department of Rheumatology, First Medical Faculty, Charles University, Prague, Czech Republic.
Lucy R WedderburnCentre for Adolescent Rheumatology Versus Arthritis, UCL Great Ormond Street Institute of Child Health, University College London, London, UK; NIHR Biomedical Research Centre at Great Ormond Street Hospital, London, UK.
Myositis Genetics Consortium
Chris WallaceCambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), University of Cambridge, Cambridge, UK; Department of Medicine, University of Cambridge, Cambridge, UK; MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.

Funding

Environmental/genetic Risk Factors and Pathogenesis of Autoimmune DiseaseZIAES101074 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI RIDER, LISA · 2009 to 2025
$34.6M
Duke Center for Advancement of Child Health (CAtCH)K12HD105253 · NICHD · DUKE UNIVERSITY · PI Corinne Mary Linardic, Ann M. Reed · 2021 to 2026
$1.5M
Intramural NIH HHS ZIA ES101074NICHD NIH HHS K12 HD105253Wellcome Trust
6 · The paper itself

Abstract

Genome-wide association studies (GWASs) have been successful at finding associations between genetic variants and human traits, including the immune-mediated diseases (IMDs). However, the requirement of large sample sizes for discovery poses a challenge for learning about less common diseases, where increasing volunteer numbers might not be feasible. An example of this is myositis (or idiopathic inflammatory myopathies [IIM]s), a group of rare, heterogeneous autoimmune diseases affecting skeletal muscle and other organs, severely impairing life quality. Here, we applied a feature engineering method to borrow information from larger IMD GWASs to find new genetic associations with IIM and its subgroups. Combining this approach with two clustering methods, we found 17 IMDs genetically close to IIM, including some common comorbid conditions, such as systemic sclerosis and Sjögren's syndrome, as well as hypo- and hyperthyroidism. All IIM subtypes were genetically similar within this framework. Next, we colocalized IIM signals that overlapped IMD signals, and found seven potentially novel myositis associations mapped to immune-related genes, including BLK, IRF5/TNPO3, and ITK/HAVCR2, implicating a role for both B and T cells in IIM. This work proposes a new paradigm of genetic discovery in rarer diseases by leveraging information from more common IMD, and can be expanded to other conditions and traits beyond IMD.

Indexed as

Genetic Predisposition to DiseaseGenome-Wide Association StudyMyositisAutoimmune DiseasesHumansImmune System DiseasesPolymorphism, Single Nucleotide

Identifiers

PMID39044428
PMCPMC11350499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.